Wire · opportunities
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
The FDA approved tavapadon (Juvmo), the first selective D1/D5 receptor agonist for Parkinson disease, expanding treatment options with demonstrated efficacy in early and levodopa-treated patients; its administration requires careful dose titration and management of CYP3A drug interactions.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 27 Sep 2026 and 29 Sep 2026.
◆ ◆ The Wire takeaway
Neurology founders need to ready operations for new CYP3A interaction complexities that tavapadon brings, prioritising pharmacist collaboration for safe dosing and patient onboarding this quarter.
◆ Coverage
4 sources · first reported 27 Sep 2026 · latest 29 Sep 2026
◆ Related on Wire
◆ Topics